Nov 12, 2020
Akero Therapeutics Reports Third Quarter 2020 Financial Results
Oct 21, 2020
Akero Therapeutics To Present At Upcoming Conferences In November
Oct 16, 2020
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
Sep 30, 2020
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study
Sep 28, 2020
Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
Sep 24, 2020
Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
Aug 12, 2020
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Jul 07, 2020
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Jun 30, 2020
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
Jun 29, 2020
Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001
Jun 17, 2020
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
May 26, 2020
Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference
Mar 31, 2020
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
Mar 16, 2020
Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Jan 08, 2020
Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference
Dec 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Nov 13, 2019
Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
Sep 04, 2019
Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
Aug 12, 2019
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results